• Swissmedic accepts review of Takeda and TiGenix’s file on Cx601 pharmaceutical-technology
    June 28, 2017
    The Swiss Agency for Therapeutic Products (Swissmedic) has accepted a review of Takeda and TiGenix’s file on investigational compound Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.
PharmaSources Customer Service